Guangzhou, February 25, 2025 — ZSeefunge Pharmaceutical Technology Co., Ltd. ("Seefunge"), an innovative ophthalmic pharmaceutical company in China, and Zhaoke (Guangzhou) Ophthalmic Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology"; HKEX: 6622), a leading ophthalmic drug manufacturer, jointly announced the launch of Shunmin®, China's first single-dose azelastine hydrochloride eye drops free of preservatives, providing a more comprehensive treatment option for patients with allergic conjunctivitis.

Group photo of the signing representatives from Seefunge and Zhaoke Ophthalmology.

In recent years, the incidence of allergic conjunctivitis in China has been rising annually, with projections indicating that over 300 million individuals nationwide will be affected by 2030¹. The launch of azelastine hydrochloride eye drops brings new hope to patients, offering rapid symptom relief within 3 minutes and sustained efficacy for up to 10 hours². The 0.4ml single-dose preservative-free formulation is particularly suitable for chronic and recurrent cases requiring long-term management. This product not only addresses the growing clinical demand but also provides a high-quality therapeutic option for allergic conjunctivitis patients.

Representatives from Seefunge and Zhaoke Ophthalmology are in discussions about a collaboration.

The collaboration between Seefunge and Zhaoke Ophthalmology marks a significant milestone in the development of ophthalmic pharmaceuticals. By leveraging Seefunge’s strengths in product innovation and Zhaoke Ophthalmology’s commercialization expertise, the two parties aim to synergize their complementary capabilities and pioneer a new chapter in the treatment of allergic conjunctivitis. As both companies deepen their commitment to ophthalmic drug development, the field of eye care in China is poised to witness further breakthroughs, delivering safer and more efficient solutions for patients. Moving forward, Seefunge and Zhaoke Ophthalmology will continue to advance the ophthalmic health industry, bringing hope and improved vision to millions.

Seefunge and Zhaoke Ophthalmology have successfully signed a collaboration agreement.

About Zhaoke Ophthalmology Limited
Zhaoke Ophthalmology Limited (HKEX: 6622), established in 2017, is a leading ophthalmic pharmaceutical company dedicated to the research, development, production, and commercialization of ophthalmic therapies to address significant unmet global medical needs. The company was listed on the Main Board of the Hong Kong Stock Exchange on April 29, 2021.

Zhaoke Ophthalmology has built a pipeline of innovative and generic drug candidates targeting major anterior and posterior segment ocular diseases. Currently, the company is focused on advancing key products in late-stage development, including:Cyclosporine A Ophthalmic Gel (under New Drug Application (NDA) review) and NVK002 for dry eye disease; TAB014 in Phase III clinical trials for myopia progression; BRIMOCHOL™ PF and ZKY001 in preparation for Phase III trials for presbyopia and corneal epithelial defects.

These therapies collectively address five major ophthalmic conditions: dry eye disease, myopia, age-related macular degeneration (AMD), presbyopia, and corneal epithelial defects. The products are manufactured at Zhaoke’s state-of-the-art, fully operational facility in Nansha, Guangzhou.

For more information, visit: www.zkoph.com.

References:

1.Data source: Frost & Sullivan.

2.Data source: Friedlaender MH, Harris J, LaVallee N, Russell H, Shilstone J. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology. 2000;107(12):2152-2157. doi:10.1016/s0161-6420(00)00349-3.

Zhejiang Seefunge Pharmaceutical Technology Co., Ltd.:
Zhejiang Seefunge Pharmaceutical Technology Co., Ltd. is a technology-driven pharmaceutical company specializing in ophthalmic research translation and industrial incubation. Founded in 2021 in Hangzhou, Zhejiang, the company leverages its founding team’s 30 years of ophthalmic expertise to pursue an innovation-driven strategy, establishing a full-industry-chain layout in ophthalmology. Its development model integrates “R&D and clinical translation of innovative drugs” with “rapid commercialization of specialized generic drugs.”

As an emerging force in China’s ophthalmic sector, Seefunge focuses on drug R&D and industrialization, with a pipeline covering: myopia prevention and control, diabetic retinopathy, dry eye disease, ocular fatigue, allergic conjunctivitis, ocular infections, non-infectious ocular inflammation, ophthalmic surface anesthesia.

The company currently has over 20 innovative and specialized generic drug projects in development, several of which are expected to address unmet clinical needs in China. Through differentiated product strategies and continuous technological innovation, Seefunge is rapidly emerging as a globally competitive innovator in ophthalmic pharmaceuticals.

Learn more: www.seefunge.com
For business inquiries: Contact: wangn@seefunge.com